logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-7. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users, 2001 to 2005


Countries where the average trend of available data is above 50% Sero-prevalence studies (SP); diagnostic testing (DT); unlinked anonymous testing (UAT)

1 - Norway: data is from Oslo; Sweden: data is from Stockholm; Bulgaria: data is from Sofia. Lithuania: data is from Alytus city.

2 - Belgium: data is from Antwerp.

3 - United Kingdom: data is from Scotland.

4 - Lithuania: Percentage reported in 2001 based on a sample of 44 IDUs.


SB2006: Figure INF-7 part (i)

See also 'General notes for interpreting data' on the Explanatory notes and help page.

For primary sources and study details, see Table INF-11 and Table INF-0.


Reitox national focal points

Page last updated: Friday, 23 November 2007